The Journal of Infectious Diseases · 2010 · 20 citations · 8 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyAdult ImmunizationVaccinationVaccine EfficacyVaccine FormulationVaccine SafetyViral VaccinesAdjuvant Effects On EfficacyAluminum AdjuvantsAluminum In VaccinesClinicaltrials.gov RegistrationSeasonal Influenza VaccinesSplit Virion VaccinesVaccine Adjuvant TherapyVaccine Formulation Effects
A double-blind, randomized, controlled trial involving 706 adults was conducted to evaluate the immunogenicity and safety of different dosages of whole-virion or split-virion H1N1 influenza vaccines with or without aluminum adjuvant. A rapid and strong immune response was induced at day 14 after the first injection. The seroprotection rates ranged from 72.7% (95% confidence interval [CI], 62.7%-81.1%) for 5-microg whole-virion aluminum formulation to 97.0% (95% CI, 90.9%-99.7%) for 30-microg split-virion nonaluminum formulation. All formulations were well tolerated. The incidences of mild, moderate, and severe reactions were 71 (10.1%), 15 (2.1%), and 1 (0.1%) of 706 reactions, respectively. The 15-microg split-virion formulation had the best immunogenicity and safety.
8
Response to a Monovalent 2009 Influenza A (H1N1) Vaccine
Michael E. Greenberg, Michael H. Lai, Günter Härtel et al. · New England Journal of Medicine · 2009 · 494 citations · Full text
A Novel Influenza A (H1N1) Vaccine in Various Age Groups
Fengcai Zhu, Hua Wang, Jian Guo Yang et al. · New England Journal of Medicine · 2009 · 341 citations · Full text